Sign in

CIK 0001645460 · Non-accelerated filer<br>Smaller reporting company

Cue Biopharma, Inc.

Sign in to watch
Ticker
CUE
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
operating
EIN
473324577
Phone
617-949-2680
Business address
100 CHESTNUT STREET, SUITE 300, SOMERVILLE, MA, 02143
Former names
Imagen Biopharma, Inc.
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$389,304
in 3 filings

Net −$389,304. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Pace of trading Bought Sold

Who's trading

90 days

  1. Lin Shao-Lee −$305K Chief Executive Officer sold 2% of stake
  2. Ray Sumita −$52K Chief Legal Compliance Officer sold 2% of stake
  3. Meluzio Michael Vincent −$32K VP, Prin. Accounting Officer sold 2% of stake

Reading 20 more Form 4s from the SEC; this list fills in as they're read.

Date Insider Transaction Shares Price Value Owned after
2023-07-21 PASSERI DANIEL R CHIEF EXECUTIVE OFFICER Grant or award · Stock Option (right to buy) +450,000 450,000
2023-07-21 Sandercock Colin SVP, GENERAL COUNSEL Grant or award · Stock Option (right to buy) +75,000 75,000
2023-07-21 Suri Anish PRESIDENT AND CSO Grant or award · Stock Option (right to buy) +124,125 124,125
2023-04-19 Garzone Pamela Director Grant or award · Stock Option (right to buy) +40,000 40,000
2023-04-11 Verheyen Patrick Director Grant or award · Stock Option (right to buy) +40,000 40,000
2023-03-23 Kiener Peter A Director Option exercise +9,682 $2.86 $28K 9,682
2023-03-23 Kiener Peter A Director Sale −9,325 $3.28 $31K 357
2023-03-23 Kiener Peter A Director Option exercise · Stock Option (right to buy) −9,682 96,062
2023-02-16 NASSHORN PATRICIA Chief Business Officer Grant or award · Stock Option (right to buy) +97,900 97,900
2023-02-16 Suri Anish PRESIDENT AND CSO Grant or award · Stock Option (right to buy) +125,500 125,500
2023-02-16 Sandercock Colin SVP, GENERAL COUNSEL Grant or award · Stock Option (right to buy) +100,000 100,000
2023-02-16 PASSERI DANIEL R CHIEF EXECUTIVE OFFICER Grant or award · Stock Option (right to buy) +324,000 324,000
2023-02-16 Millar Kerri-Ann CHIEF FINANCIAL OFFICER Grant or award · Stock Option (right to buy) +124,000 124,000
2023-01-17 Levisetti Matteo Chief Medical Officer Grant or award · Stock Option (right to buy) +110,000 110,000
2023-01-03 Morich Frank Director Grant or award · Stock Option (right to buy) +10,000 10,000
2023-01-03 Kiener Peter A Director Grant or award · Stock Option (right to buy) +10,000 10,000
2023-01-03 HOWSON TAMAR D Director Grant or award · Stock Option (right to buy) +10,000 10,000
2023-01-03 Fletcher Aaron G.L. Director Grant or award · Stock Option (right to buy) +10,000 10,000
2023-01-03 DRISCOLL FREDERICK W Director Grant or award · Stock Option (right to buy) +10,000 10,000
2022-08-22 Millar Kerri-Ann CHIEF FINANCIAL OFFICER Shares withheld for taxes −2,828 $3.05 $9K 14,311

Page 6 of 17 · 323 trades